Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
86 hedge funds and large institutions have $1.12B invested in Loxo Oncology, Inc in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 17 reducing their positions, and 13 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 17
66% more capital invested
Capital invested by funds: $677M → $1.12B (+$447M)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
0% more funds holding
Funds holding: 86 → 86 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$54.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$25.3M |
| 5 |
DM
Deerfield Management
New York
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.63M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$6.14M |
| 3 |
JP Morgan Chase
New York
|
-$1.8M |
| 4 |
Teacher Retirement System of Texas
Austin,
Texas
|
-$1.74M |
| 5 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$1.69M |
LOXO Hedge Fund Activity: Q1 2017 in Review
86 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2017, worth a combined $1.12B — up 66% from $677M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LOXO positions and 13 closed out — a net gain of 5 holders — while 43 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $54.7M. The largest seller was Eventide Asset Management, cutting an estimated $6.63M.
- 86 institutional investors held Loxo Oncology, Inc (LOXO) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $1.12B of Loxo Oncology, Inc stock for Q1 2017, up 66% quarter-over-quarter.
- 18 funds opened new Loxo Oncology, Inc positions in Q1 2017 and 13 closed out, a net change of +5 holders.
- The largest Loxo Oncology, Inc buyer in Q1 2017 was BlackRock, an estimated $54.7M added.
- The largest Loxo Oncology, Inc seller in Q1 2017 was Eventide Asset Management, an estimated $6.63M sold.
Based on aggregated 13F filings for Q1 2017.